Long COVID Incidence Proportion in Adults and Children Between 2020 and 2024: An Electronic Health Record-Based Study From the RECOVER Initiative
- PMID: 39907495
- PMCID: PMC12272849
- DOI: 10.1093/cid/ciaf046
Long COVID Incidence Proportion in Adults and Children Between 2020 and 2024: An Electronic Health Record-Based Study From the RECOVER Initiative
Abstract
Background: Incidence estimates of post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, also known as long COVID, have varied across studies and changed over time. We estimated long COVID incidence among adult and pediatric populations in 3 nationwide research networks of electronic health records (EHRs) participating in the RECOVER (Researching COVID to Enhance Recovery) Initiative using different classification algorithms (computable phenotypes).
Methods: This EHR-based retrospective cohort study included adult and pediatric patients with documented acute SARS-CoV-2 infection and 2 control groups: contemporary coronavirus disease 2019 (COVID-19)-negative and historical patients (2019). We examined the proportion of individuals identified as having symptoms or conditions consistent with probable long COVID within 30-180 days after COVID-19 infection (incidence proportion). Each network (the National COVID Cohort Collaborative [N3C], National Patient-Centered Clinical Research Network [PCORnet], and PEDSnet) implemented its own long COVID definition. We introduced a harmonized definition for adults in a supplementary analysis.
Results: Overall, 4% of children and 10%-26% of adults developed long COVID, depending on computable phenotype used. Excess incidence among SARS-CoV-2 patients was 1.5% in children and ranged from 5% to 6% among adults, representing a lower-bound incidence estimation based on our control groups. Temporal patterns were consistent across networks, with peaks associated with introduction of new viral variants.
Conclusions: Our findings indicate that preventing and mitigating long COVID remains a public health priority. Examining temporal patterns and risk factors for long COVID incidence informs our understanding of etiology and can improve prevention and management.
Keywords: COVID; EHRs; electronic health records; long COVID; public health surveillance.
© The Author(s) 2025. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.
Conflict of interest statement
Potential conflicts of interest . H. P., K. G. T., C. R. O., A. V., L. E. T., J. D., R. A. M., J. D. K., E. W. K., P. A. K., R. S. G., C. R. G., A. D., T. W. C., M. H., and K. R. T. all reports funding from the NIH. Additionally, J. A. reports grants or contracts from Pfizer and Amgen. C. G. C. reports a leadership role on the World Health Organization (WHO) Medical Scientific Advisory Committee. P. A. K. reports a leadership role with the Commonwealth of Virginia Board of Health. L. C. K. reports owning shares in Amgen, Regeneron, Sanofi, and GLAXF. K. E. R. reports funding from the NIH (National Institute on Minority Health and Health Disparities [NIMHD]) and the US Department of Agriculture (USDA). C. R. O. reports holding leadership positions with the American Academy of Pediatrics, Eastern Society of Pediatric Research, and Journal of Pediatric Infectious Diseases Society. S. E. P. received funding from the National Institute of Mental Health (NIMH) and travel support from Columbia University Mailman School of Public Health. J. L. S. reports funding from NYU Langone. K. R. T. reports funding from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), NIMHD, NIH Director's Office, Centers for Disease Control and Prevention (CDC), Travere, and Bayer; consulting fees and/or payments/honoraria from Eli Lilly, Boehringer Ingelheim, AstraZeneca, Bayer, Novo Nordisk, Pfizer, Travere, and ProKidney; participation in a data safety monitoring or advisory board for NIDDK/NIH and AstraZeneca; and leadership roles with the American Society of Nephrology and Clinical Journal of the American Society of Nephrology. L. E. T. reports a leadership position with the American Journal of Public Health. L. M. reports a leadership position with the International Society of Nurses in Genetics. C. K. reports receiving payments from the NIH. J. D. K. reports funding from the VA and CDC. K. C. H. reports owning stock in Pfizer. M. H. reports being a founder of Alamya Health. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.
Update of
-
Long COVID incidence in adults and children between 2020 and 2023: a real-world data study from the RECOVER Initiative.Res Sq [Preprint]. 2024 Apr 26:rs.3.rs-4124710. doi: 10.21203/rs.3.rs-4124710/v1. Res Sq. 2024. Update in: Clin Infect Dis. 2025 Jul 18;80(6):1247-1261. doi: 10.1093/cid/ciaf046. PMID: 38746290 Free PMC article. Updated. Preprint.
References
-
- National Heart, Lung, and Blood Institute (NHLBI) . Long COVID Research and Resources. NHLBI.NIH.gov. Available at: https://www.nhlbi.nih.gov/covid/long-covid. Accessed 5 February 2025.
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous